<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099344</url>
  </required_header>
  <id_info>
    <org_study_id>ABCA-001</org_study_id>
    <nct_id>NCT02099344</nct_id>
  </id_info>
  <brief_title>Artegraft Versus Propaten Dialysis Grafts</brief_title>
  <official_title>A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare Artegraft and Propaten grafts for use in dialysis access to see if one performs
      better than the other. How long each one lasts until a complication arises or until the graft
      is no longer used will be compared.

      The study hypothesis is that the Artegraft, being an actual blood vessel, will work better
      than the manufactured Propaten graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis
      will be randomized to receive one of these two grafts as part of their standard care.
      Patients will be assessed at 2-3 weeks post-operatively and again at 6 and 12 months for flow
      characteristics, dialysis adequacy and graft associated complications such as stenosis,
      infection and thrombosis. Data on urea reduction ratio (URR), kinetic modeling (Kt/V), and
      access flow (QB) will be collected at 3, 6, 9 and 12 months via phone call to the
      hemodialysis center in order to evaluate patency and function.

      Access complications (stenosis, thrombosis, infection) will be treated per our standard
      protocol. These data will be recorded and then primary, assisted primary and secondary
      patency rates will be calculated and the graft arms compared using life table analysis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Objective: The Primary Objective is to Assess the Primary, Primary Assisted and Secondary Patency Rate of Each Graft</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome will be determined by Kaplan-Meier life table analysis. Patency determination will be from access creation until the first occlusion of the graft.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine Incidence of Complications in Patients Receiving the Artegraft Bovine Graft vs. Gore Propaten Graft</measure>
    <time_frame>12 months</time_frame>
    <description>Complication incidence will be collected from the time of access creation until the graft fails and is abandoned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>ESRD</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Artegraft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propaten</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artegraft</intervention_name>
    <description>Surgical placement of graft for hemodialysis access</description>
    <arm_group_label>Artegraft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Propaten</intervention_name>
    <description>Surgical placement of graft for hemodialysis access</description>
    <arm_group_label>Propaten</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  Candidate for hemodialysis

          -  Not a candidate for native AV fistula

          -  In need of a new AV graft in the upper arm location

          -  Artery and vein &gt; 3mm.

          -  Medically stable and have a life expectancy of ≥ 12 months

          -  The patient or legal guardian understands the study and is willing to comply with the
             requirements.

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  Current history or within 6 months of IV drug abuse

          -  Chronic hypotension (&lt;100 mm systolic pressure) not responsive to treatment

          -  Pregnant or lactating

          -  Known hypercoagulable state

          -  Requires only a revision of an existing graft

          -  Receiving artery or vein is less than 3 mm in diameter at the time of implantation

          -  Known axillary/subclavian occlusion or stenosis that has not been treated

          -  Known or suspected systemic infection

          -  Heparin sensitivity (known HIT)

          -  Enrolled in another investigational study.

          -  Subject has more than 1 graft in target limb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earl Schuman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente Northwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2014</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>June 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2016</results_first_posted>
  <last_update_submitted>June 3, 2016</last_update_submitted>
  <last_update_submitted_qc>June 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Propaten</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
        <group group_id="P2">
          <title>Artegraft</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propaten</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
        <group group_id="B2">
          <title>Artegraft</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Objective: The Primary Objective is to Assess the Primary, Primary Assisted and Secondary Patency Rate of Each Graft</title>
        <description>The primary outcome will be determined by Kaplan-Meier life table analysis. Patency determination will be from access creation until the first occlusion of the graft.</description>
        <time_frame>12 months</time_frame>
        <population>Data not collected due to early study termination</population>
        <group_list>
          <group group_id="O1">
            <title>Propaten</title>
            <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
          </group>
          <group group_id="O2">
            <title>Artegraft</title>
            <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Objective: The Primary Objective is to Assess the Primary, Primary Assisted and Secondary Patency Rate of Each Graft</title>
          <description>The primary outcome will be determined by Kaplan-Meier life table analysis. Patency determination will be from access creation until the first occlusion of the graft.</description>
          <population>Data not collected due to early study termination</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine Incidence of Complications in Patients Receiving the Artegraft Bovine Graft vs. Gore Propaten Graft</title>
        <description>Complication incidence will be collected from the time of access creation until the graft fails and is abandoned.</description>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One patient enrolled, study stopped before any AE's occurred</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Propaten</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
        <group group_id="E2">
          <title>Artegraft</title>
          <description>Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
Artegraft: Surgical placement of graft for hemodialysis access
Propaten: Surgical placement of graft for hemodialysis access</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Earl Schuman, MD</name_or_title>
      <organization>Kaiser Permanente NW</organization>
      <phone>503-331-6017</phone>
      <email>kathleen.ann.arnold@kpchr.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

